EWTX

NEUTRALAnalyst

Edgewise Therapeutics, Inc.

2026-03-24

Price

$30.64

+2.82%

Score4.8Watchlist

Signals4/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.9xvs 20d avg

Analysis

EWTX is surging against the tape because idiosyncratic clinical success is completely overriding the broader geopolitical RISK_OFF regime. Positive 3.5-year efficacy data for its muscular dystrophy drug sevasemten recently triggered a massive JPMorgan price target upgrade to $45, fueling High-Conviction Price Discovery. Technical signals, including a PERFECT_STACK and BOLLINGER_SQUEEZE, confirm that institutional buyers are aggressively absorbing any macro-induced selling pressure. This structural relative strength (+4.3% vs SPY) highlights the stock's role as a non-correlated safe haven while the rest of the equity market panics over oil spikes and inflation.

Fired Signals

STEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSMA BOUNCE

Key Takeaways

Actionable Thesis: EWTX is a non-correlated breakout candidate, driven by de-risked clinical data and a $45 price target that isolates it from the ongoing geopolitical macro shock.
Key Risk: At a 6x Price-to-Book premium, the stock is highly sensitive to any pipeline setbacks or delays in the upcoming GRAND CANYON pivotal cohort.
What to Watch: Monitor the $27.82 structural support level to ensure the BOLLINGER_SQUEEZE resolves upward, alongside upcoming Phase 2 data for cardiovascular drug EDG-7500.

← Back to 2026-03-24 View Full EWTX History →Yahoo Finance &nearr;